Foghorn Therapeutics Inc. Annual Operating Income (Loss) in USD from 2019 to 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Foghorn Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2024.
  • Foghorn Therapeutics Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$24M, a 5.71% increase year-over-year.
  • Foghorn Therapeutics Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$103M, a 4.84% increase year-over-year.
  • Foghorn Therapeutics Inc. annual Operating Income (Loss) for 2024 was -$103M, a 4.84% increase from 2023.
  • Foghorn Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$108M, a 7.88% increase from 2022.
  • Foghorn Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$117M, a 16.3% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$103M +$5.22M +4.84% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-06
2023 -$108M +$9.23M +7.88% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-06
2022 -$117M -$16.4M -16.3% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-07
2021 -$101M -$32.2M -47% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 -$68.5M -$17.4M -34.2% Jan 1, 2020 Dec 31, 2020 10-K/A 2022-08-09
2019 -$51.1M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.